Development and Application of a Data-Driven Signal Detection Method for Surveillance of Adverse Event Variability Across Manufacturing Lots of Biologics-Reference-Cited by-同舟云学术

Development and Application of a Data-Driven Signal Detection Method for Surveillance of Adverse Event Variability Across Manufacturing Lots of Biologics

Published:2023-09-29 Issue:11 Volume:46 Page:1117-1131
ISSN:0114-5916
Container-title:Drug Safety
language:en
Short-container-title:Drug Saf

Author:

Wilde Joshua T.^ORCID,Springs Stacy^ORCID,Wolfrum Jacqueline M.^ORCID,Levi Retsef^ORCID

Funder

U.S. Food and Drug Administration

Publisher

Springer Science and Business Media LLC

Subject

Pharmacology (medical),Pharmacology,Toxicology

Link

https://link.springer.com/content/pdf/10.1007/s40264-023-01349-6.pdf

Reference28 articles.

1. Harpaz R, DuMouchel W, Shah NH, Madigan D, Ryan P, Friedman C. Novel data-mining methodologies for adverse drug event discovery and analysis. Clin Pharmacol Ther. 2012;91:1010–21.

2. Khouri C, Nguyen T, Revol B, Lepelley M, Pariente A, Roustit M, et al. Leveraging the variability of pharmacovigilance disproportionality analyses to improve signal detection performances. Front Pharmacol. 2021;12:1–7.

3. Kulldorff M, Dashevsky I, Avery TR, Chan AK, Davis RL, Graham D, et al. Drug safety data mining with a tree-based scan statistic. Pharmacoepidemiol Drug Saf. 2013;22:517–23.

4. Sandberg L, Taavola H, Aoki Y, Chandler R, Norén GN. Risk factor considerations in statistical signal detection: using subgroup disproportionality to uncover risk groups for adverse drug reactions in VigiBase. Drug Saf. 2020;43:999–1009. https://doi.org/10.1007/s40264-020-00957-w.

5. Beninger P. Opportunities for collaboration at the interface of pharmacovigilance and manufacturing. Clin Ther. 2017;39:702–12. https://doi.org/10.1016/j.clinthera.2017.03.010.